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Abstract
 
The immune system, despite its complexity, is maintained at a relative steady state. Mechanisms
involved in maintaining lymphocyte homeostasis are poorly understood; however, recent
availability of transgenic (Tg) and knockout mouse models with altered balance of lymphocyte
cell populations suggest that cytokines play a major role in maintaining lymphocyte homeosta-
sis. We show here that transforming growth factor (TGF)-
 
b
 
 plays a critical role in maintaining
CD8
 
1
 
 T cell homeostasis in a Tg mouse model that specifically overexpresses a dominant neg-
ative TGF-
 
b
 
 II receptor (DNRII) on T cells. DNRII T cell Tg mice develop a CD8
 
1
 
 T cell
lymphoproliferative disorder resulting in the massive expansion of the lymphoid organs. These
CD8
 
1
 
 T cells are phenotypically “naive” except for the upregulation of the cell surface mole-
cule CD44, a molecule usually associated with memory T cells. Despite their dominance in the
peripheral lymphoid organs, CD8
 
1
 
 T cells appear to develop normally in the thymus, suggest-
ing that TGF-
 
b
 
 exerts its homeostatic control in the peripheral immune system.
Key words: lymphoproliferative disorder • T lymphocyte subsets • TCR repertoire • T cell 
transformation • thymocyte development
 
Introduction
 
TGF-
 
b
 
 is a member of a large family of secreted proteins
involved in cell growth and differentiation (for review see
reference 1). This protein family, known as the TGF-
 
b
 
superfamily, consists of many structurally conserved mem-
bers that function by several distinct mechanisms depen-
dent on the species, cell type, or cell environment in-
volved.
Mammalian TGF-
 
b
 
 is itself a multifunctional subfamily
that consists of three isoforms (TGF-
 
b
 
1–3) that have been
shown to have similar functions in vitro but appear to have
unique functions in vivo based on tissue expression and
activity (2). In the immune system, TGF-
 
b
 
 has been
shown to have two major effects, a proinflammatory effect
and an immunosuppressive effect (3). Both of these effects
are elicited by all three isoforms and are regulated by mul-
tiple control mechanisms, including regulation of cell ad-
hesion (4–6), modulation of macrophage function (7–9),
and regulation of lymphocyte proliferation and differentia-
tion (10–12).
In the absence of TGF-
 
b
 
1, mice develop a massive
multifocal inflammatory disease, suggesting a major role
for TGF-
 
b
 
1 in immune regulation (13, 14). Further analy-
sis has shown that the disease consists of an initial inflam-
matory response followed by an autoimmune manifesta-
tion (15–17). Dissection of these two phenomena has been
 
possible by crossing TGF-
 
b
 
1 knockout (KO)
 
1
 
 mice to
other immune-deficient mice. TGF-
 
b
 
1 KO mice crossed
to SCID mice result in mice with no inflammatory lesions
or indications of autoimmunity (15), implying a role for B
and T cells. Similarly, if TGF-
 
b
 
1 KO mice are crossed to
MHC class II–deficient mice, they no longer develop an
inflammatory or autoimmune-type disease, implicating an
MHC class II–restricted T cell component in the disease
(18). However, because of the multiple effects of TGF-
 
b
 
,
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it is difficult to characterize the actions of TGF-
 
b
 
 as spe-
cific to T cells in the murine KO models.
Regulation of homeostasis in the immune system is
complex. Lymphocytes are maintained at relatively con-
stant numbers and ratios when no foreign antigens are de-
tected. Rapid expansion of lymphocyte number follows
antigen encounter, with eventual return to preimmune
stimulation numbers and ratios after antigen removal. Anti-
gen type and route of entry, as well as previous antigen en-
counters, determine which populations of lymphocytes ex-
pand and differentiate and which ones remain quiescent
(19–22). Much is known about the activation, differentia-
tion, and expansion of lymphocytes involved in such anti-
gen responses, but little is known about the maintenance of
lymphocyte homeostasis before and after the response.
Recent studies using transgenic (Tg) and KO mice have
shown that a multitude of these mice have defects in lym-
phocyte homeostasis. Many of the defects in these mice in-
volve cytokines or their signaling pathways (23–26). De-
fects in the common cytokine receptor 
 
g
 
 (present in IL-2,
IL-4, IL-7, IL-9, and IL-15 receptors) or its signaling path-
way result in an overexpansion of CD4
 
1
 
 T cells (23, 24).
Likewise, a CD4
 
1
 
 Th cell imbalance occurs in mice defec-
tive for the interferon regulatory factor 1 and the IL-2 gene
(27, 28). A second category of genetically altered mice ex-
hibiting lymphocyte homeostatic defects involves genes
important in negative regulation. Fas, Fas ligand, and
CTLA-4 are examples of genes that result in a severe lym-
phoproliferative disease when defective in mice (29, 30).
Interestingly, TGF-
 
b
 
 is both a negative regulator of the
immune system and a cytokine; however, its role in lym-
phocyte homeostasis has been difficult to analyze because
of its diverse effects on multiple organ systems. To better
study the role of TGF-
 
b
 
 in T cells and its effect in vivo, we
have generated a Tg mouse that expresses a dominant neg-
ative TGF-
 
b
 
 type II receptor (DNRII) specifically on T
cells (31, 32) using a human CD2 promoter/enhancer (33).
This model is distinct from the TGF-
 
b
 
1 KO model; since
it would be expected to have a interruption in signaling
from all three isoforms of TGF-
 
b
 
, it would not be ex-
pected to interfere with stem cell development (34), and it
would not influence endothelial cell adhesiveness (5).
Rather, a T cell–specific, DNRII Tg mouse allows direct
investigation of the role of TGF-
 
b
 
 on T cell number and
function in vivo.
Mice expressing a DNRII transgene on their T cells de-
velop a CD8
 
1
 
 T cell hyperproliferation that dominates the
lymphocyte population by 2–9 mo of age. These CD8
 
1
 
 T
cells express multiple TCR V-
 
b
 
 families, suggesting a poly-
clonal expansion of CD8
 
1
 
 T cells; however, over time oli-
goclonal populations of TCR V-
 
b
 
 families appear in most
mice. In contrast to the TGF-
 
b
 
1 KO mice, this expansion
of T cells is limited to the CD8
 
1
 
 T cell population and
does not involve CD4
 
1
 
 T cells or B cell populations, nor
does it have an inflammatory component. These results
suggest that TGF-
 
b
 
 plays a critical role in maintaining
CD8
 
1
 
 T cell homeostasis.
 
Materials and Methods
 
Gene Constructs.
 
A 0.7-kb fragment containing the DNRII
with a 5
 
9
 
 influenza hemagglutinin (HA) tag cloned into
pcDNRIIA3 (Invitrogen Corp.) was removed with HindIII (5
 
9
 
)
and XhoI (3
 
9
 
). It was inserted into Bluescript SKII (Stratagene
Inc.) at the 5
 
9 
 
HindIII and 3
 
9
 
 XhoI sites. The DNRII transgene
fragment was then removed from Bluescript using XhoI (5
 
9
 
) and
XbaI (3
 
9
 
) and then reinserted into Bluescript SKII at the 5
 
9 
 
SmaI
and 3
 
9 
 
XbaI sites. The DNRII transgene was then removed with
EcoRI and cloned into the CD2 minigene (33) at the EcoRI site.
The construct was removed from the vector using a 5
 
9 
 
SalI site
and a 3
 
9
 
 NotI site and purified over a sucrose gradient for injec-
tion.
 
Mice.
 
DNRII Tg mice were generated and housed at the
Science Applications International Corp. Tg core facility in Fred-
erick, MD according to National Institutes of Health (NIH) ani-
mal guidelines. All Tg mice were generated and maintained with
C57BL/6 strain mice.
 
Cell Populations.
 
Splenocytes, LN cells, and thymocytes were
prepared as previously described (35). T cell populations were
purified from splenocytes by either magnetic bead separation
(Miltenyi Biotec) or passage over a T cell column (Biotex Labs.),
followed by magnetic bead separation. Purity of the T cell popu-
lations was established by flow cytometric analysis and was always
 
.
 
85%. Cells were maintained in complete culture medium
(CCM): RPMI 1640 (Life Technologies, Inc.) with 1 mM so-
dium pyruvate (Life Technologies), 100 mM nonessential amino
acids (Life Technologies), 100 U/ml penicillin plus 100 mg/ml
streptomycin (Life Technologies), 50 mM 2-ME (Fisher Scien-
tific Co.), 2 mM 
 
l
 
-glutamine (Life Technologies), and 10% FCS
(Hyclone). Cells were incubated at 37
 
8
 
C with 5% CO
 
2
 
/95% air.
Cell line TG1124 was generated from Tg founder T12H1 by
incubation of splenocytes with Con A (2.5 
 
m
 
g/ml; Sigma Chem-
ical Co.) in CCM. A stable, long-term cell line, TG1124,
emerged from this culture and was carried by successive passes in
CCM alone.
 
Flow Cytometry.
 
Biotin-, FITC-, and PE-conjugated mAbs
against mouse CD8 (Calbiochem Corp.), CD4, CD25, CD44,
CD45Rb, CD69, and TCR V-
 
b
 
 panel (PharMingen) were used
to stain cells from thymus, LN, and spleen. Anti-HA (Boehringer
Mannheim) was used at 1 
 
m
 
g/ml. Biotin-conjugated (1 
 
m
 
g/ml)
Abs were incubated in a total volume of 20 
 
m
 
l for 20 min on ice,
washed once in FACS media (FM; HBSS [GIBCO BRL] plus
1% BSA [Sigma Chemical Co.] plus 1% azide [wt/vol; Sigma
Chemical Co.]). A secondary reagent, streptavidin R–PE (Caltag
Labs.) used at 1:40 dilution was used in conjunction with biotin-
modified reagent. An F
 
c
 
-specific Ab, 2.4G2, was used to block F
 
c
 
binding. Secondary reagent was added in 20 
 
m
 
l of total volume,
incubated for 15 min on ice, washed in FM twice, and then re-
suspended in 0.3 ml of FM. Stained cells were analyzed by FAC-
Scan™ (Becton Dickinson) as previously reported (35). Data are
presented on log scale as either histogram or dot plot.
 
Semiquantitative Reverse Transcriptase–PCR.
 
T Cells were iso-
lated using magnetic cell sorting using MACS microbeads (Mil-
tenyi Biotec). T cells were separated from non-T cells by positive
selection using anti-Thy 1.2–conjugated microbeads or were
sequentially purified by positive selection using anti-CD8–conju-
gated microbeads followed by positive selection using anti-CD4–
conjugated microbeads. In both procedures, the non-T cell frac-
tion was the final eluate and gave similar results with both methods.
RNA was prepared by the Trizol
 
®
 
 method (Life Technologies).
cDNA was prepared using the Superscript
 
®
 
 choice system (Life 
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Technologies), and PCR was performed as previously described
(35), except conditions were optimized to generate PCR prod-
ucts in a linear range. Southern hybridization was performed on
the PCR products using specific 
 
32
 
P-labeled internal oligonucle-
otides. Radioactivity was detected using a PhosphorImaging
screen (Eastman Kodak Co.) with a Storm 860 analyzer (Molecu-
lar Dynamics). Data were analyzed using ImageQuant
 
®
 
 software
(Molecular Dynamics).
 
Cross-linking Assay.
 
Equal amounts of total protein from ei-
ther non-Tg splenocytes or TGF-
 
b
 
 T cell lines were used as pre-
viously described (36). In brief, 
 
125
 
I-labeled TGF-
 
b
 
1 was incu-
bated with either C57BL/6 splenocytes or DNRII T cell line
TG1124 in the absence or presence of cold TGF-
 
b
 
1. After cross-
linking, lysates were immunoprecipitated with either anti–TGF-
 
b
 
type II receptor, directed at the cytoplasmic tail, or anti-HA
mAb. Immunoprecipitates were run on a polyacrylamide gel and
analyzed as previously described (36).
 
Cell Cycle Analysis.
 
Splenocytes were harvested as previously
described, washed in FM, and stained with anti-CD4 FITC or
anti-CD8 FITC mAb. Stained cells were washed twice in cold
FM and fixed with a 0.5% formaldehyde solution. Cells were
treated with a citrate hypotonic solution containing propidium
iodide to stain for DNA (37). Cells were analyzed on a FAC-
Scan™ (Becton Dickinson) and analyzed using ModFit LT
 
®
 
(Becton Dickinson) cell cycle analysis software as previously de-
scribed (37).
 
Results
 
Generation of DNRII Tg Mouse.
 
To target the DNRII
transgene to the T cell lineage, a truncated TGF-
 
b
 
 type II
receptor containing an HA tag sequence (reference 36; Fig.
1 A) was inserted into the human CD2 minigene construct.
Expression of the DNRII transgene was evaluated by an
 
125
 
I-labeled TGF-
 
b
 
1 binding assay, demonstrating surface
expression of DNRII capable of binding its ligand in T
cells of Tg mice (Fig. 1 B). Transgene expression was also
confirmed by semiquantitative reverse transcriptase (RT)-
PCR (Fig. 1, C and D) and Northern blot analysis (data
not shown). No appreciable amount of DNRII transgene
mRNA was detected in T cell–depleted populations, as de-
termined by RT-PCR (Fig. 1 C). Both CD4
 
1
 
 and CD8
 
1
 
T cells expressed comparable amounts of DNRII transgene
mRNA, as determined by RT-PCR (Fig. 1 D).
Seven Tg lines (T12I2, TI2El, T12E2, T12G2, Tl2H1,
T12I3, and T12#9) were identified by Southern blot anal-
Figure 1. Construction and expression of the
DNRII transgene. (A) Schematic representation
of the expression vector with transgene. (B) As-
sociation of TGF-b1 with DNRII. Either sple-
nocytes (SP) from C57BL/6 mice or TG1124
cells (TG) were affinity labeled with 125I–TGF-
b1 in the absence (2) or presence (1) of cold
TGF-b1. Cell lysates were subjected to immu-
noprecipitation by either anti–TGF-b II recep-
tor, specific for cytoplasmic tail of endogenous
TGF-b II, or anti-HA tag, specific for DNRII.
Immunoprecipitation of receptors was analyzed
by SDS-PAGE and autoradiography. (C) Semi-
quantitative RT-PCR to establish tissue-spe-
cific expression of DNRII transgene. CSK, a
ubiquitously expressed kinase, was used to es-
tablish relative expression of the transgene in T
cell and non-T cell populations (number in pa-
rentheses). (D) Semiquantitative RT-PCR to
establish expression within T cell subsets. Ex-
pression of G3PDH was used to calculate rela-
tive expression between CD41 and CD81 T
cell subsets (number in parentheses). 
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ysis; five transmitted the transgene to offspring. Offspring
that were Tg for the DNRII gene were born at the ex-
pected Mendelian frequency and appeared healthy at birth.
However, over time all seven Tg founder mice and their
offspring developed a severe lymphoproliferative disorder
resulting in enlarged spleen (2–20
 
3
 
) and LNs (2–50
 
3
 
),
with moderate infiltration of lymphocytes into other or-
gans. The severity of the disease phenotype varied among
founders and correlated with transgene copy number.
Founder T12Hl had the most severe phenotype as well as
the highest transgene copy number (five to six copies)
among the six transmitting founders (data not shown), with
a marked infiltration of all lymphoid organs with small
lymphocytes (Fig. 2). Other organs, such as the liver, heart,
and lungs, had moderate infiltration of similar small lym-
phocytes with minimal inflammation (Fig. 2). Founder
Tl2H1 died at 3 mo of age but was able to transmit the
transgene to one female Fl mouse. The female T12H1 off-
spring also died at 3 mo of age with a phenotype similar to
that of the founder.
Founders T12I2 and T12E1 had a similar phenotype to
T12H1, except for a slower onset. Founder T12E1 was
found to have a single integration site containing two to
four copies of the transgene (data not shown). Founder
T12I2 was found to have two independent integration
sites, each with one to two copies of the transgene (data
not shown). T12I2 offspring containing either of the two
integrated transgenes were phenotypically similar, with
Figure 2. Small lymphocyte infiltration in DNRII Tg founder T12H1. (A) Extensive perivascular infiltration of small lymphocytes into the lung with
little inflammation. (B) Higher magnification showing lymphoid cells in alveolar walls. (C) Spleen containing large white pulp areas with disruption of
normal architecture. (D) Higher magnification showing a uniform population of lymphoid cells. (E) Liver with extensive perivascular and periportal lym-
phoid infiltration, with many lymphoid cells present in the blood but little inflammation. (F) Higher magnification showing infiltration around the blood
vessel and in the sinusoids. Magnifications: A, 753; C and E, 503; B, D, and F, 1503. 
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each having a slower onset of the phenotype than the
founder.
Phenotypic Analysis of DNRII Tg Mice. Analysis of cell
surface phenotype of splenocytes and LN cells from
founder TI2H1 revealed a 10-fold increase in the number
of CD81 T cells as compared with control (Fig. 3), sug-
gesting that the lymphoproliferative disorder was based
solely on a CD81 T cell expansion. In concordance with
this observation, absolute cell numbers of CD41 T cells
and B cells were only slightly decreased when compared
with control (Fig. 3). All DNRII Tg founders and their
offspring exhibited a similar increase in CD81 cell numbers
resulting in a severe CD4/8 ratio alteration (data not
shown), suggesting that the phenotype was integration site
independent.
Further T cell surface marker phenotype analysis was
performed to identify the activation status of the CD81 T
cells. Lymphocytes from DNRII Tg mice were stained for
CD44, CD69, CD25, CD45Rb, and CD62L. Normal na-
ive CD81 T cells express low levels of CD44, CD69, and
CD25 and high levels of CD45Rb and CD62L. DNRII
Tg CD81 T cells had a striking increase in CD44 levels
(Fig. 4) yet unchanged levels of CD25, CD62L, CD69,
and CD45Rb (Fig. 4). Increased levels of CD69 have been
detected in a small percentage of the DNRII Tg mice stud-
ied, all of which have had the most severe progression of
the lymphoproliferative disorder (data not shown).
Time Course Analysis of Phenotypic Changes. CD81 T
cell changes were consistent in all of the DNRII Tg
founder lines studied, with each progressing in a similar
manner toward a CD81 T cell dominance. To better char-
acterize this progression, a time course analysis of cell sur-
face marker expression was performed. The CD44hi phe-
notype was the earliest observed abnormality, with high
CD44 levels occurring on CD81 T cells by 6–12 wk of age
(Fig. 5 A). Similar time points in slower-progressing DN-
RII Tg lines (T12I2) indicate that the Tg mice have nor-
mal percentages of CD44hi cells at 4–6 wk, establishing that
initial CD81 T cell populations are normal with respect to
CD44 phenotype (data not shown). No changes were ob-
served in the cell surface phenotype of the DNRII Tg
CD41 T cells (data not shown). Between 12 and 24 wk of
age, a second major change occurred. The percentage of
CD81 T cells began to rise, causing a significant decrease in
the CD4/CD8 ratio (Fig. 5 A). This decreased CD4/CD8
ratio was mostly a result of an absolute increase in CD81 T
cells, not a decrease in CD41 T cells (Fig. 3).
To address the issue of monoclonal or polyclonal expan-
sion, changes in the TCR V-b repertoire were measured
using a panel of mAbs. These data demonstrate that the
CD81 T cell repertoire was being skewed from a poly-
Figure 3. Flow cytometric analysis of B and T cells in DNRII Tg
mice. Splenocytes from 12-wk-old founder T12H1 (right panels) or an
aged-matched C57BL/6 mouse (left panels) were analyzed for expression
of T cell markers, CD4 and CD8 (top panels), and B cell markers, B220
and MHC class II (CII) molecules (bottom panels). Absolute cell num-
bers 31026 shown in parentheses. At least 10,000 events were collected
for each group.
Figure 4. T cell activation marker expression on surfaces of DNRII Tg
CD81 T cells. LN T cells from 27-wk-old non-Tg littermate mouse (left
histograms) or DNRII Tg mouse I2A1 (right histograms) were stained
with Abs specific for a panel of T cell activation/memory markers. At
least 10,000 events were collected for each group.1192 Dominant Negative TGF-b II Receptor Alters T Cell Homeostasis
clonal to an oligoclonal repertoire, containing several TCR
V-b families (Fig. 5 B). Finally, in late onset of the lym-
phoproliferative disorder, one to two TCR V-b family
usually dominated between 6 and 12 mo of age. However,
no one TCR V-b family dominated across individual
mice, suggesting that the TCR V-b expansion was not due
to a single environmental antigen (data not shown).
Thymocyte Development in DNRII Tg Mice. This gross
overpopulation of the lymphoid organs in DNRII Tg mice
can be explained by an increase in production of CD81 T
cells from the thymus, decreased cell death of CD81 T
cells, or an expansion of CD81 T cells in the periphery.
The thymi of DNRII Tg mice, despite a dominance of
CD81 T cells in the periphery, have a normal appearance
and normal subpopulation phenotype (Fig. 6 A). Although
increased thymic export of CD81 cells is a formal possibil-
ity, this observation rather suggested that the expansion of
CD81 cells was due to a lack of cell death, a profound pro-
liferation in the periphery, or a combination of both.
Cell Cycle Analysis of CD81 T Cell Populations. To dif-
ferentiate between these possibilities, cell cycle analysis of
CD81 T cells from the DNRII Tg mice was performed. It
was found that whereas normal lymphocytes from C57BL/6
mice (Fig. 6 B) had very few cells in cycle, DNRII Tg
CD81 T cells resembled the cell cycle status of C57BL/6
(Fig. 6 B) or DNRII Tg (data not shown) thymocytes,
with 5–8% of cells in cycle. These data suggest that DNRII
Tg CD81 T cells are actively dividing, which could ac-
count for their overpopulation in the periphery of DNRII
Tg mice. No increased resistance to apoptosis was detected
in Tg CD81 T cells when compared with normal T cells
when incubated for various time periods in vitro or sub-
jected to cytokine withdraw after activation (data not
shown), suggesting that CD81 T cell proliferation rather
than resistance to cell death is responsible for the CD81 T
cell expansion found in DNRII Tg mice.
Discussion
The immune system is maintained at a steady state, with
distinct populations of cells held at a relatively constant
number and ratio. This homeostatic mechanism is
especially apparent within T lymphocyte subpopulations,
where a constant CD4/CD8 ratio is maintained. Studies
have shown that this constant CD4/CD8 ratio is main-
tained even when T cells varying in initial CD4/CD8 ra-
tios are used to reconstitute athymic mice (38, 39). In addi-
tion, it appears that naive and memory T cells, based on
cell surface expression of the CD441 marker, are also
strictly interrelated, with neither population able to fully
Figure 5. Time course analysis of CD81 pe-
ripheral T cells in DNRII Tg mice. (A) PBLs
from founder line E1A3 (h) or non-Tg litter-
mate mice (s) were analyzed by flow cytome-
try for T cell markers CD4 and CD8 (left; ex-
pressed as CD4/CD8 ratio) and CD81CD44hi
surface marker (right) over time. (B) TCR V-b
repertoire was measured by a panel of TCR
V-b–specific mAbs. Percentage of CD81 PBLs
expressing a specific TCR V-b receptor was
plotted over time. At least 10,000 events were
collected per time point.1193 Lucas et al.
reconstitute T cell numbers by itself (40). Together, these
data suggest that interactions between T lymphocyte sub-
populations are strictly regulated.
DNRII-expressing T cells alter this strict T cell homeo-
static process by allowing a massive expansion of CD81
CD44hi cells in the periphery. Absolute numbers of CD41
T cells, as well as B cells, remained unchanged or slightly
decreased over time; however, slight increases in the num-
ber of CD41 cells in cycle have been detected, indicating
that CD41 T cells may be affected by the transgene. The
CD81 T cell expansion is directly proportional to the dose
of TGF-b DNRII expression in the Tg line, as demon-
strated by varying rates of CD81 T cell expansion by differ-
ent Tg founder lines. Similar dose-dependent effects have
been seen in other TGF-b DNRII Tg mice (41).
These results are quite distinct from those for TGF-b1
KO mice, which develop a severe inflammatory disease
with diverse infiltrating cell populations. These differences
between the two mouse models may be explained by the
differences in the tissues affected by the genetic alterations.
Whereas the TGF-b DNRII transgene directly affects only
T lymphocytes, the TGF-b1 KO alteration affects many
tissues, including tissues vital to the survival of the mouse
(13, 14). In addition, TGF-b1 gene inactivation affects
only TGF-b1 signaling, whereas the TGF-b DNRII trans-
gene affects signaling from all three isoforms of TGF-b,
which may contribute to differences seen between the two
mouse models.
Differential expression of the transgene in CD41 and
CD81 T cells does not appear to be a likely explanation for
Figure 6. Thymic development and cell cycle
analysis of DNRII Tg T cells. (A) LN cells (top
panels) or thymocytes (bottom panels) from 27-
wk-old DNRII Tg line I2A1 (right panels) or lit-
termate control mice (left panels) were stained with
anti-CD4 and -CD8 mAbs and were detected by
flow cytometric analysis. (B) CD81 LN T cells
(four leftmost panels) or thymocytes (right panels)
from 19-wk-old DNRII Tg line I2C2 (center pan-
els) or littermate control mice (left and right panels)
were stained with propidium iodide (PI). Percent-
age of cells in cycle (S/M/G2) is indicated as per-
centage of incorporation of PI as detected by flow
cytometric analysis. Thymocytes (right panels) were
used as a positive control for the detection of cy-
cling cells. At least 10,000 events were collected for
each group.1194 Dominant Negative TGF-b II Receptor Alters T Cell Homeostasis
the discrepancies, as RT-PCR analysis demonstrated equal
amounts of transgene mRNA in both populations. In addi-
tion, other Tg mice using the same expression vector have
had equal expression in CD41 and CD81 T cells (33, 42,
43). Similarly, all founder mice, regardless of transgene
copy number, had the same phenotype, which would indi-
cate that high transgene expression, which was capable of
causing massive CD81 T cell expansion by 8 wk of age,
was not sufficient to cause a major change in the CD41 T
cell population.
Differential control of CD41 and CD81 T cell homeo-
stasis has been observed repeatedly in recent gene KO
models. Most strikingly, defects in cytokines binding to re-
ceptors containing the common cytokine receptor g chain
have altered lymphocyte homeostasis dramatically (23, 24,
28, 44–46). However, many changes that occur in these
mice can be attributed to abnormal thymic development.
One exception appears to be the IL-2R complex that
shows normal thymic development when disrupted but ab-
normal expansion of CD41 cells in the periphery over time
(28, 46, 47). Similarly, CTLA-4 KO mice appear to have
normal T cell development in the thymus, but these mice
rapidly develop a T cell lymphoproliferative disease in the
periphery characterized by an activated T cell phenotype
that appears to be mediated by CD41 T cells (30, 48, 49).
Thymic development appears to be normal in the TGF-b
DNRII Tg mouse, despite a gross overpopulation of CD81
T cells in the LNs and spleen. This type of CD81 T cell
expansion has been infrequently observed in other Tg or
KO mouse models but is commonly observed with viral
infections. Massive CD81 T cell expansion has been ob-
served with lymphocytic choriomeningitis, murine CMV,
pichinde virus, and vaccinia virus and has been associated
with CMV, Epstein-Barr virus, and Kawasaki disease in
humans, which is thought to be caused by an infectious
agent (50–55). Like virally induced CD81 T cell expan-
sions, CD81 T cells in TGF-b DNRII Tg mice are associ-
ated with an oligoclonal expansion with a CD44hi pheno-
type. However, unlike virally induced CD81 T cells,
CD81 T cells in TGF-b DNRII Tg mice do not express
IL-2Ra, which could be upregulated by an antigen-spe-
cific release of IL-2 not found in TGF-b DNRII Tg mice
(data not shown). Alternatively, expression of certain T
cell activation markers could have been transiently altered
(56, 57).
Similar differential stimulation of CD81 T cells over
CD41 T cells has also been observed with low doses of
LPS in vivo (58). These responses, as well as the CD81 T
cell expansion seen in viral infections, are thought to be in-
duced by type I IFN (IFN-I) secreted by APCs (59). This
idea is supported by the results of Tough et al. (60) show-
ing an increase in CD81CD44hi T cells in mice injected
with IFN-I. CD81 T cells in these mice are CD69lo
CD252, suggesting that the T cells expanding in TGF-b
DNRII Tg mice might be induced by a similar mecha-
nism.
If similar mechanisms are involved, one could hypothe-
size that TGF-b normally acts as a negative regulator of
CD81 T cell expansion in an unchallenged immune sys-
tem. When encountering antigen capable of stimulating an
IFN-I response, TGF-b negative regulation is reversed, al-
lowing CD81 T cells to enter the cell cycle. This would
result in an increased pool of available CD81 T cells capa-
ble of interacting with the foreign antigen.
Several recent reports support this hypothesis. One re-
port describes a direct inhibitory link between the IFN-g
signaling pathway and the TGF-b signaling pathway (61).
As IFN-g is also induced by many of the same agents that
induce IFN-I, as well as by IFN-I itself, the presence of
IFN-I could reverse the negative regulation of TGF-b, al-
lowing CD81 T cell expansion. A second report demon-
strates that IFN-I can stimulate IL-15 production, which is
capable of selectively expanding a CD81CD44hi T cell
population in vivo (45). CD81 T cell homeostasis may thus
involve a complex influence of many cytokines, with
TGF-b acting as a major negative regulator.
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